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Abstract:  
 
Bioactivity-directed fractionation of the organic extracts of two filamentous fungi of the 
Bionectriaceae, strains MSX 64546 and MSX 59553 from the Mycosynthetix library, led to the 
isolation of a new dimeric epipolythiodioxopiperazine alkaloid, verticillin H (1), along with six 
related analogues, Sch 52900 (2), verticillin A (3), gliocladicillin C (4), Sch 52901 (5), 11′-
deoxyverticillin A (6), and gliocladicillin A (7). The structures of compounds 1–7 were 
determined by extensive NMR and HRMS analyses, as well as by comparisons to the literature. 
All compounds (1–7) were evaluated for cytotoxicity against a panel of human cancer cell lines, 
displaying IC50 values ranging from 1.2 µM to 10 nM. Compounds 1–5 were examined for 
activity in the NF-κB assay, where compounds 2 and 3 revealed activity in the sub-micromolar 
range. Additionally, compounds 1, 3, and 4 were tested for EGFR inhibition using an enzymatic 
assay, while compound 3 was examined against an overexpressing EGFR+ve cancer cell line. 
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INTRODUCTION 
 
Dimeric epipolythiodioxopiperazine (ETP) alkaloids are bioactive secondary metabolites 
reported to have potent cytotoxic1–10 and antibacterial activities,11–16 along with 
antiparasitic,17 nematicidal,18 antiviral,19and immunosuppressive properties.20 This class of 
compounds has been isolated largely from several terrestrial and marine fungi, including species 
of the Leptosphaeria, Chaetomium, Tilachlidium, Verticillium, Gliocladium, 
and Penicillium genera.21 The densely functionalized and stereochemically-complex core of 
these alkaloids, coupled with their potent biological activities, presents an attractive target for 
drug leads. Although the ETP alkaloids have been known for over four decades, with 
chatecocin22 and verticillin A16,23, 24 first described in 1970, only 23 other natural analogues have 
been described since then. The first total synthesis (11,11'-dideoxyverticillin A),25 which stymied 
chemists for nearly 40 years, was hailed inScience.26 Ongoing studies by this same 
group27 resulted in a synthetic strategy to generate the di-, tri-, and tetrasulfides, (+)-chaetocin A, 
(+)-chaetocin C, and (+)-12,12′-dideoxychetracin A, respectively, with complete stereochemical 
control in thiolation and precision in the degree of sulfidation. The mechanism of action for the 
potent cytotoxicity of the ETPs has not been fully elucidated. However, several different 
activities have been described, including: generation of reactive oxygen species (ROS) through 
oxidation of the polysulfide bridge,2 intracellular induction of the c-fos proto-
oncogene,28 inhibition of the epidermal growth factor receptor (EGFR) tyrosine kinase 
activity,3 and more recently, apoptosis activation by BNIP3 (19 kDa interacting protein-3) 
upregulation and/or tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) 
sensitizer.29 Interest in these compounds remains high, due to both their potent biological 
activities and interesting chemistry. 
 
As part of ongoing studies to discover new anticancer drug leads from filamentous fungi,30, 31 the 
organic-soluble extracts of solid substrate fermentation of fungi of the Bionectriaceae, cultures 
MSX 64546 and MSX 59553 from the Mycosynthetix library, exhibited cytotoxic activity 
against MCF-7 (breast), H460 (large cell lung), and SF-268 (astrocytoma) human cell lines that 
was indicative of IC50 values < 2 µg mL−1 for the crude extracts. Preliminary LC-HRMS 
dereplication procedures suggested the presence of the known ETP, verticillin A (3), as well as 
characteristic fragmentation patterns for related and possibly new ETPs, both of which likely 
contributed to the cytotoxicity of the extracts. Therefore, bioactivity-directed fractionations were 
initiated using H460 cancer cells to monitor the purifications, and this led to the isolation of a 
new ETP, verticillin H (1), along with six known verticillin-type compounds, Sch 52900 (2), 
verticillin A (3), gliocladicillin C (4), Sch 52901 (5), 11′-deoxyverticillin A (6), and 
gliocladicillin A (7). All pure isolates were assessed for cytotoxicity against additional cancer 
cell lines. Compounds 1–5 were examined in an NF-κB inhibition assay, while compounds 1, 3, 
and 4 were tested in vitro for EGFR inhibition using an enzymatic assay, and 3 was examined 
against an overexpressing EGFR+ve cancer cell line. 
 
RESULTS AND DISCUSSION 
 
Identification of ETPs 
 
Bioactivity-directed purification of the organic extracts of fungal strains MSX 64546 and MSX 
59553 led to the isolation of seven cytotoxic ETPs (1–7; see Figure 1), including the new 
compound, verticillin H (1). An LC-HRMS dereplication procedure (Figure 2), which utilized 
molecular formula, exact mass, and UV maxima (204, 240, and 301 nm) as search criteria in the 
Dictionary of Natural Products and SciFinder databases, coupled with NMR analysis of pure 
isolates (Table S1), confirmed that compounds 2–7 belong to the ETP class of fungal natural 
products. The data for the known compounds matched the literature for Sch 52900 
(2),28 verticillin A (3),23 gliocladicillin C (4),32 Sch 52901 (5),28 11′-deoxyverticillin A (6),9 and 
gliocladicillin A (7);1 Table S1 compiles the 1H and 13C data for these compounds in CDCl3. 
 
 
 
Figure 1. Structure of compounds (1–7) isolated from fungi MSX 64546 and MSX 59553. 
 
 
 
Figure 2. LC-UV-MS dereplication for compounds 1–7 and the ETPs rich fraction from fungus 
MSX 59553 
Structure elucidation of verticillin H (1) 
 
The HRMS data of compound 1 yielded a molecular formula C32H32N6O6S4. The IR data 
suggested the presence of carbonyl (1673 cm−1), hydroxy (3402 cm−1), and aromatic (1685 and 
1429 cm−1) moieties. The UV spectrum of 1 exhibited absorption maxima at 204, 240, and 301 
nm, as observed with similar epipolythiodioxopiperazine analogues.9, 15, 23, 24 Although the 13C 
NMR spectrum showed resonances for 16 carbons (Table 1), inspection of the HRMS data, 
which suggested 32 carbons, revealed a symmetrical dimeric structure. Detailed analysis of 
HMBC and HSQC data for compound 1 (Table 1) showed similarities to verticillin A (3); 
however, the molecular weight of 1 was 28 greater than that of 3. This suggested the presence of 
an additional methylene unit in each half of the molecule, which was evidenced by the 
resonances at δH 2.4, 2.1 (for H2-13/H2-13') that were coupled to a methyl doublet of doublets at 
δH 1.2 (H3-14/H3-14'). In addition, HMBC correlations of the methyl proton signals H3-14/H3-14' 
with the quaternary carbon C-3/C-3' (δC 77.0), the secondary carbon C-13/C-13' (δC 24.6), and 
the amide carbonyl C-4/C-4' (δC 161.5), established the connection of the ethyl side chain to 
position C-3 and C-3' in each monomeric unit. In turn, these two units were connected via the C-
10b to C-10b' bond by virtue of HMBC correlations of the methine proton H-5a/H-5a' (δH 5.7) 
with the quaternary carbons C-6a/C-6a' (δC 148.9), C-10b/C-10b' (δC 65.8), and C-11a/C-11a' 
(δC 77.5), respectively; such a connection was consistent with other ETP alkaloids in the 
literature.9, 11, 15, 24 All other NMR data and HMBC correlations for 1 were consistent with the 
structural assignment (Figure 1), and compound 1 was ascribed the trivial name verticillin H. 
The absolute configuration of 1 was determined by comparison of the optical rotation values and 
CD spectra with those reported for several verticillin analogues.9, 11, 15 
 
 
 
 
Table 1. NMR data for compound 1 [in CDCl3, 500 (1H) and 125 (13C) MHz, chemical shifts in 
δ, coupling constants in Hz] 
 
Biological activity 
 
Inhibition of cancer cell proliferation in vitro All isolates (1–7) were evaluated for cytotoxic 
activity against HT-29, H460, SF-268, MCF-7, and MDA-MB-435 cell lines (see Table 2). 
Previously, Erkel et al.20 reported the cytotoxicity of 2 against HL60 (leukemia) cells; Katagiri et 
al.23 described the effect of 3 against the Ehrlich ascites carcinoma in mice and HeLa cells; and 
Che et al.32 showed that 4 exhibited high cytotoxic activity on A549 (adenocarcinoma) and 
HepG2 (hepatocellular carcinoma) human cell lines. However, this is the first report of the 
simultaneous evaluation of 1–7 against all the cancer cell lines listed above. In general, all of the 
compounds displayed potent cytotoxicity, approaching the activity of the positive controls. 
However, as suggested by Gardiner et al.,21 side chain modifications did not change the 
cytotoxicity of these compounds drastically. 
 
 
Table 2. Cytotoxicity against a panel of human tumor cell lines and NF-κB inhibitory activity of 
compounds isolated from MSX 64546 and MSX 59553 
 
Transcription Factor NF-κB assay Phal et al.33 reported the inhibition of NF-κB in cells by 
glyotoxin, the first monomeric ETP characterized from Gliocladium fimbriatum.21 The inhibitory 
effect of this compound was attributed to a possible interaction within an essential thiol residue 
of the cysteine rich extracellular domains of the protein.21, 33 Since NF-κB factor is an integral 
part of the inflammatory immune response and controls expression of some cytokines, its 
inhibition may account for the cytotoxic and immunosuppressive properties of dimeric ETPs. 
Compounds 1–5 were examined for NF-κB inhibitory activity (Table 2). 
Compounds 2 and3 inhibited the specific binding ability of activated p65 subunits of NF-κB in 
the nucleus of HeLa cells with IC50 values of 0.5 and 0.1 µM, respectively, being approximately 
a half-order of magnitude less potent than the positive control (rocaglamide). These results were 
in agreement with the recently reported effect of verticillin A (3) as a sensitizer of human colon 
carcinoma cells to TRAIL-induced apoptosis.29 
 
Epidermal growth factor receptor activity 11,11′-Dideoxyverticillin, a structurally-related ETP 
isolated from the traditional Chinese medicinal herb Shiraia bambusicola,3 showed tyrosine 
kinase inhibitory activity in a cell-free ELISA assay against the epidermal growth factor receptor 
(EGFR), the vascular endothelial growth factor receptor-1/fms-like tyrosine kinase-1 (VEGFR-
1/Flt-1), and the human epidermal growth factor receptor-2 (HER2/ErbB-2), with activity in the 
nM range for the former two and µM range for the latter. To the best of our knowledge, those 
studies represent the first report of enzymatic inhibition of dimeric ETPs. Based on those results, 
compounds 1, 3, and 4 were tested for EGFR inhibition using a luminescence kinase assay, but 
none of these substances were found to be active (IC50 values >10 µM; positive control lapatinib, 
IC50 13 nM; Figure 3). To further assess whether these compounds exert their cytotoxic activity 
in an EGFR-dependent manner by targeting EGFR expression/activity in a cellular system, 
compound 3 was tested for cytotoxicity against EGFR+ and EGFR− (EGFR+ve and HuTu-80, 
respectively) cell lines. Figure 4 (top panel) shows Western immunoblot data that indicates no 
EGFR protein versus very high EGFR protein levels in HuTu-80 and EGFR+ve cells, 
respectively. However, such a large difference in EGFR levels among the two cell lines did not 
result in any biological differences in the activity of compound3 in these two cell lines (Figure 4; 
lower panels). Together, these observations suggest that the agent has strong cytotoxic activity 
independent of cellular EGFR levels. We have not identified 11,11′-dideoxyverticillin in the 
cultures we have studied to date. Hence, we have not been able to determine if the literature data 
are reproducible. 
 
 
 
Figure 3. Inhibitory effects of compounds 1, 3 and 5 and the positive control, lapatinib, on 
EGFR activity. 
 
 
 
Figure 4. EGFR level of expression on HuTu-80 and EGFR+ve cell lines and cytotoxicity after 
treatment with compound 3 [HuTu-80 (A) and EGFR+ve (B)]. 
 
CONCLUSIONS 
 
Using bioactivity-directed fractionation and a LC-UV-HRMS dereplication protocol, one new 
compound, along with six known ETPs were isolated from the organic extracts of two fungi of 
the Bionectriaceae (strains MSX 64546 and MSX 59553). The isolated ETPs were potently 
cytotoxic against a panel of human cell lines in culture. Compounds 1–5 were tested for NF-κB 
inhibitory activity, with compounds 2 and 3having IC50 values in the sub-micromolar range. 
Based on literature precedence, some of the isolates were examined for activity vs EGFR; 
however, no activity was observed when tested against both enzyme-based and cell-based assays. 
Regardless, the potent cytotoxicity of these compounds, which was on the same order of 
magnitude as the positive control, camptothecin, coupled with the promising NF-κB activity, 
warrants further exploration of the ETPs. 
 
MATERIALS AND METHODS 
 
General 
 
Optical rotations, UV spectra, IR spectra, and CD spectra were obtained on a Rudolph Research 
Autopol III polarimeter (Rudolph Research, Hackettstown, NJ, USA), a Varian Cary 100 Bio 
UV-vis spectrophotometer (Varian Inc., Walnut Creek, CA, USA), a Perkin-Elmer Spectrum 
One with Universal ATR attachment (Perkin-Elmer, Waltham, MA, USA), and an Olis DSM 17 
CD spectrophotometer (Olis, Bogard, GA, USA), respectively. NMR experiments were 
conducted in CDCl3 using a JEOL ECA-500 (operating at 500 MHz for 1H and 125 MHz for 13C; 
JEOL Ltd., Tokyo, Japan). HRESIMS data were measured using an electrospray ionization (ESI) 
source coupled to a Q-TOF Premier mass spectrometer (Waters Corp., Milford, MA, USA) or a 
LTQ Orbitrap XL system (Thermo Fisher Scientific, San Jose, CA, USA) in both positive and 
negative ionization modes and by either direct injection or via a liquid 
chromatographic/autosampler system that consisted of a Acquity UPLC system (Waters Corp.). 
Flash chromatography was conducted using a CombiFlash Rf system using a RediSep Rf Si-gel 
Gold column (both from Teledyne-Isco, Lincoln, NE, USA). HPLC was carried out on Varian 
Prostar HPLC systems equipped with Prostar 210 pumps and a Prostar 335 photodiode array 
detector, with data collected and analyzed using Galaxie Chromatography Workstation software 
(version 1.9.3.2, Varian Inc.). For preparative HPLC, a Synergi Max-RP (4 µm; 250 × 21 mm; 
Phenomenex, Torrance, CA, USA) or a YMC ODS-A (5 µm, 250 × 20 mm; Waters Corp.) 
column was used. For semipreparative HPLC, a YMC ODS-A (5 µm, 250 × 10 mm; Waters 
Corp.) column was used. A Gemini-NX (5 µm; 250 × 4.6 mm; Phenomenex) column was used 
for analytical HPLC. For UPLC analysis, a BEH C18 (1.7 µm; 50 × 2.1 mm; Waters Corp.) 
column was used. 
 
LC-UV-HRMS Dereplication Procedure 
 
UPLC-HRESIMS conditions Sample concentration, 1.0 mg mL−1 MeOH-Dioxane (1:1) 
solution; mobile phase (UPLC Acquity): gradient elution of CH3CN–0.1% aqueous formic acid 
(0–1.0 min, 20:80; 1.0–5.0 min, from 20:80 to 100% CH3CN and hold for 2 min); UV detection 
wavelengths, 210 and 254 nm; flow rate, 0.3 mL/min; injection volume, 3 µL. ESI conditions 
(Thermo LTQ Orbitrap XL): capillary temperature, 275 °C; sheath gas, 15; auxiliary gas, 5; 
sweep gas, 2; source voltage, 4.50 kV; capillary voltage, 46 V; tube lens, 115 V. Mass range was 
set to optimally pass ions from m/z 100–2000. Data were acquired in centroid mode during the 
LC run. 
 
Data analysis Using a combination search of proposed molecular formulas, exact mass, and UV 
maxima corresponding to the major peaks in the Dictionary of Natural Products (Chapman and 
Hall, London, UK) and SciFinder databases (Chemical Abstracts Service, Columbus, OH, USA), 
the samples with unknown molecular formulas were designated for further purification. 
 
Producing Organisms and Fermentations 
 
Mycosynthetix fungal strains 64546 and 59553 were isolated by Dr. Barry Katz in May of 1992 
and January of 1992 from leaf litter and leaves, respectively. DNA analyses were performed by 
MIDI Labs (Newark, DE, USA), and the D2 variable region of the large subunit rRNA was 
sequenced and compared with their database, which suggested that these fungi belong to the 
Bionectriaceae family (order Hypocreales); the sequences were deposited in Genbank (accession 
numbers JQ749727 and JQ749725 for MSX 64546 and MSX 59553, respectively). The cultures 
were stored on malt extract slants and transferred periodically. Fresh cultures were grown on 
similar slants, and a piece of each culture was transferred individually to a medium containing 
2% soy peptone, 2% dextrose and 1% yeast extract (YESD media). Following incubation (7 
days) at 22°C with agitation, the cultures were used to inoculate 50 mL of rice media, prepared 
using rice to which was added a vitamin solution and twice the volume of rice with H2O, in 250 
mL Erlenmeyer flasks. These were incubated at 22°C until the cultures showed good growth 
(~14 days) to generate the screener cultures. The scale-up cultures were treated in a similar 
manner but grown in 2.8-L Fernbach flasks (Corning, Inc., Corning, NY, USA) containing 150 g 
rice and 300 mL H2O. These were inoculated using the seed cultures grown in the YESD media 
and were incubated at 22°C for 14 days. 
 
Extraction and Isolation 
 
To the small scale cultures on rice were added 60 mL of 1:1 MeOH-CHCl3, and the mixtures 
were shaken for 16 h on a reciprocating shaker. The solutions were filtered, and equal volumes 
of H2O and CHCl3 were added to the filtrate to bring the total volume to 250 mL. The solutions 
were stirred vigorously for 1 h, partitioned in a separatory funnel, and the bottom, organic layers 
were concentrated by rotary evaporation to dryness. Then, each extract was defatted by stirring 
vigorously for 1 h in a mixture of 50 mL MeOH, 50 mL CH3CN and 100 mL hexane and then 
partitioned in a separatory funnel. The bottom layers were collected and evaporated to dryness. 
The scale-up solid fermentations on rice were extracted using the same procedures, except that 
the extraction volumes were adjusted as follow: 500 mL of 1:1 MeOH-CHCl3mixture, equal 
volumes of H2O and CHCl3 to a total volume of 2 L, and a mixture of 150 mL MeOH, 150 mL 
CH3CN and 200 mL hexane for the defatting process. Each defatted large scale extract (602 mg 
and 3.2 g for MSX 64546 and MSX 59553, respectively) was adsorbed onto a minimal amount 
of Celite 545 (Acros Organics, Geel, Belgium) and dried with mixing via a mortar and pestle. 
The materials were fractionated separately at 40 mL/min on a RediSep Rf Gold Si-gel column 
(40 g), first with 100% hexanes for 0.7 column volumes (CV) followed by a gradient of 100% 
hexanes to 100% CHCl3 over 8.9 CV. The elution continued with 100% CHCl3 for 7.4 CV, then 
with a gradient of MeOH in CHCl3 (0–2% over 9.7 CV, then 2–5% over 5.2 CV, then 5–10% 
over 5.2 CV, then 10–20% over 3.7 CV, then 20–100% over 2.2 CV. MeOH (100%) was finally 
held for a further 6.7 CV. Fractions were collected every 25 mL and pooled according to UV and 
ELSD profiles. From MSX 64546, compounds 1–5 were present in fractions 19–29, which were 
combined and evaporated (229.8 mg; IC50 values < 2.0 µg mL−1 against H460 cells). This pooled 
fraction was then subjected to preparative HPLC (Synergi Max-RP column, 20–100% CH3CN in 
0.1% aqueous formic acid over 30 min; fractions collected every 0.5 min). Further purification of 
the subsequent fractions by semipreparative HPLC (various ratios of CH3CN in 0.1% aqueous 
formic acid) afforded compounds 1(1.6 mg), 2 (0.8 mg), 3 (2.3 mg), 4 (2.5 mg), and 5 (4.9 mg). 
From MSX 59553, compounds 1, 3, and 5were present in fractions 34–56, while 
compounds 2, 4, 6, and 7 were present in fractions 57–61. These two sets of fractions were 
combined and evaporated individually (108.5 and 132.7 mg, respectively; IC50 values < 2.0 µg 
mL−1 against H460 cells). The combined pool of the former (fractions 34–56) was then subjected 
to preparative HPLC (YMC ODS-A, 20–100% CH3CN in 0.1% aqueous formic acid over 30 
min; fractions collected every 0.5 min). Further purification of the subsequent fractions by 
semipreparative HPLC (various ratios of CH3CN in 0.1% aqueous formic acid) afforded 
compounds 1 (3.0 mg), 3 (2.1 mg), and 5 (5.5 mg). The combined pool of the latter (fractions 
57–71) was subjected to preparative HPLC using the same conditions and column. Further 
purification of the subsequent fractions by semipreparative HPLC (various ratios of CH3CN in 
0.1% aqueous formic acid) afforded compounds 2 (8.5 mg), 4 (15.5 mg), 6 (6.0 mg), and7 (11.8 
mg). 
 
Verticillin H (1) 
 
Compound 1 was isolated as a white amorphous solid (4.6 mg); [α]D25 +440 (c 0.1 CHCl3); UV 
(MeOH) λmax (log ε) 204 (4.79), 240 (2.84), and 301 (3.79) nm; IR (diamond) νmax 3522, 2939, 
1685, 1429, and 1376 cm−1; CD (MeOH) λmax (Δε) 235 (+62.1), 270 (−5.9), 304 (+8.6), and 373 
(−1.2) nm; 1H NMR (CDCl3, 500 MHz) and 13C NMR (CDCl3, 125 MHz), see Table 
1 and Supplementary Information (Figures S1–S6); HRESIMS (positive mode) m/z 725.1326 
[M+H]+ (calcd for C32H33N6O6S4, 725.1339), (negative mode) m/z 723.1189 [M–H]− (calcd for 
C32H31N6O6S4, 723.1193). 
 
Cytotoxicity Assay 
 
The cytotoxicity measurements against the MCF-734 human breast carcinoma (Barbara A 
Karmanos Cancer Center), NCI-H46035 human large cell lung carcinoma [HTB-177, American 
Type Culture Collection (ATCC)], SF-26836 human astrocytoma (NCI Developmental 
Therapeutics Program), HT-2937 human colorectal adenocarcinoma (HTB-38, ATCC) and the 
MDA-MB-43538 human melanoma (HTB-129, ATCC) cell lines were performed as described in 
detail previously.39 
 
NF-κB p65 Assay 
 
An ELISA based NF-κB inhibitory assay was performed as described previously.39 Rocaglamide 
(Enzo Life Sciences, Inc., Farmingdale, NY, USA) was used as a positive control (IC50 value of 
0.075 µM). 
SUPPLEMENTARY MATERIAL 
 
Experimental protocol EGFR tyrosine kinase assay. 
Figure S1 1H NMR of verticillin H (1) in CDCl3. 
Figure S2 13C NMR of verticillin H (1) in CDCl3. 
Figure S3 1H-1H COSY NMR of verticillin H (1) in CDCl3. 
Figure S4 1H-1H NOESY NMR of verticillin H (1) in CDCl3. 
Figure S5 1H-13C HSQC NMR of verticillin H (1) in CDCl3. 
Figure S6 1H-13C HMBC NMR of verticillin H (1) in CDCl3. 
Table S1 NMR data for compound 2−7 (in CDCl3, 500 (1H) and 125 (13C) MHz, chemical shifts 
in δ, coupling constants in Hz) 
 
Experimental protocol EGFR tyrosine kinase assay. 
 
Testing against the epidermal growth factor receptor (EGFR) was conducted by BPS Biosciences 
(San Diego, CA, USA). The assay, as per protocol of Kinase-Glo Plus luminescence kinase assay 
kit (Promega; Madison, WI, USA), measures the kinase activity by quantitating the amount of 
ATP remaining in solution following a kinase reaction.  
 
Assay conditions. Test compounds (test range 0.3 nM to 10 µM) were diluted in 10% DMSO and 
5 µL of the dilution was added to a 50µL reaction so that the final concentration of DMSO is 1% 
in all of reactions. The enzymatic reactions were conducted at 30 °C for 25 minutes in a 50 µL 
mixture containing EGFR assay buffer, 10 M ATP, and the test compound. After the 
enzymatic reaction, 50 µL of Kinase-Glo Plus Luminescence kinase assay solution (Promega) 
was added to each reaction and the reaction was performed at room temperature for 5 minutes. 
Luminescence signal was measured using a BioTek Synergy 2 (Winooski, VT, USA) microplate 
reader. EGFR activity assays were performed in duplicate at each concentration.  
Data analysis. The luminescence data were analyzed using the computer software, Graphpad 
Prism (La Jolla, CA, USA). The difference between luminescence intensities in the absence of 
EGFR (Lut) and in the presence of EGFR (Luc) was defined as 100% activity (Lut – Luc). Using 
luminescence signal (Lu) in the presence of the compound, % activity was calculated as: 
% activity = [(Lut − Lu)/(Lut − Luc)] × 100, where Lu = the luminescence intensity in the 
presence of the compound. The IC50 value was determined by the concentration causing a half-
maximal percent activity. EGFR inhibitor, lapatinib, was used as positive control. 
 
 
 
 
 
Figure S1 1H NMR of verticillin H (1) in CDCl3 (500 MHz). 
 
 
 
 
 
 
 
 
 
 
 
Figure S2 13C NMR of verticillin H (1) in CDCl3 (125 MHz). 
 
 
 
 
 
 
 
 
 
 
 
Figure S3 1H-1H COSY NMR of verticillin H (1) in CDCl3. 
 
 
 
 
 
 
 
 
 
 
 
Figure S4 1H-1H NOESY NMR of verticillin H (1) in CDCl3. 
 
 
 
 
 
 
 
 
 
 
Figure S5 1H-13C HSQC NMR of verticillin H (1) in CDCl3. 
 
 
 
 
 
 
 
 
 
 
Figure S6 1H-13C HMBC NMR of verticillin H (1) in CDCl3. 
 
 
 
 
 
 
 
 
 
 
Table S1 NMR data for compound 2−7 in CDCl3 (1H and 13C at 500 and 125 MHz, respectively) 
 
 
 
 
 
 
 
 
 
 
Table S1 (cont.) NMR data for compound 2−7 (1H and 13C at 500 and 125 MHz, respectively) 
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FOOTNOTES 
 
Supporting Information. Experimental protocol for the EGFR tyrosine kinase assay, 1D and 
2D NMR spectra for verticillin H (1), and NMR data for known compounds 2–7. Supplementary 
Information accompanies the paper on The Journal of Antibiotics website 
(http://www.nature.com/ja). 
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